RE: Excellent business model8 Jan 2021 09:53
Agree in the main, pardariff.
The tests and BAMS come under number 5.
1 to 4 is repeatable, e.g., LG Chem for up to £1bn.
Given the worldwide potential of successful tests, Avacta must believe that the potential of the best tests outweighs the shorter term. I hope it does as well.
Judging by the number of variants that are cropping up and whether these are covered by the vaccines or not, I like the therapy collaboration with Daewoong.
All the best.